Street Calls of the Week
ROTTERDAM - Erasmus University Medical Center in Rotterdam has become the first hospital in the Netherlands to successfully use the Genesis Robotic Magnetic Navigation System from Stereotaxis (NYSE:STXS), a medical technology company whose stock has surged over 46% in the past six months, according to a company statement released Monday. According to InvestingPro data, the company’s current market capitalization stands at approximately $256 million.
The Genesis system represents the latest advancement in robotic magnetic navigation technology for cardiac ablation procedures, which are used to treat arrhythmias - abnormal heart rhythms that affect tens of millions of people worldwide. This expansion comes as Stereotaxis demonstrates strong revenue growth of nearly 34% over the last twelve months, based on InvestingPro analysis, which offers comprehensive insights through its Pro Research Reports covering over 1,400 US stocks.
Dr. Sing-Chien Yap, Director of Electrophysiology at Erasmus Medical Center, noted the clinical benefits of the new system. "We are impressed with the speed and responsiveness of Genesis. Combined with the MAGiC Catheter we are particularly pleased with the synergistic additive improvements to robotic magnetic navigation," Dr. Yap said.
Erasmus MC has established itself as a global leader in robotic magnetic navigation technology, having performed over 4,500 procedures with Stereotaxis technology. The center treats various patients with arrhythmias, including children and those with congenital heart disease or complex arrhythmia conditions.
The robotic system is designed to provide precision and safety benefits during cardiac ablation procedures, which are minimally invasive treatments for arrhythmias. When left untreated, these heart rhythm abnormalities can increase the risk of stroke, heart failure, and sudden cardiac arrest.
David Fischel, Stereotaxis Chairman and CEO, acknowledged the long-term partnership with Erasmus MC’s electrophysiology team and expressed commitment to supporting their robotic program.
Stereotaxis technology has been used to treat over 150,000 patients globally across the United States, Europe, Asia, and other regions, the press release stated. While the company maintains a "Fair" financial health score according to InvestingPro analysis, investors can access additional insights and 7 key ProTips about the company’s performance through an InvestingPro subscription.
In other recent news, Stereotaxis Inc. reported its second-quarter 2025 earnings, revealing a revenue of $8.8 million. This figure significantly exceeded analyst expectations, which were set at $7.75 million. The company’s earnings per share (EPS) were reported at -$0.05, surpassing the forecasted -$0.07. These results indicate a positive earnings surprise for Stereotaxis. Despite this, the stock saw a decline in after-hours trading. Analysts had anticipated different outcomes, and the market’s complex reaction reflects this. These developments highlight Stereotaxis’ financial performance and market dynamics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.